Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total value of $437,550.00. Following the sale, the chief executive officer owned 2,175,000 shares in the company, valued at approximately $190,334,250. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Trading Up 3.1%

NASDAQ:IRMD opened at $93.17 on Friday. The stock has a market cap of $1.19 billion, a P/E ratio of 50.91 and a beta of 0.90. The stock’s 50-day moving average is $92.91 and its 200-day moving average is $95.13. iRadimed Corporation has a 1-year low of $50.88 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The company had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts forecast that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is 43.72%.

Analyst Upgrades and Downgrades

IRMD has been the topic of several analyst reports. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Roth Mkm reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, iRadimed presently has a consensus rating of “Buy” and an average target price of $120.00.

Institutional Trading of iRadimed

Institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC boosted its holdings in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 397 shares during the last quarter. CWM LLC boosted its holdings in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP bought a new stake in iRadimed in the third quarter valued at approximately $40,000. State of Alaska Department of Revenue bought a new stake in iRadimed in the third quarter valued at approximately $47,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.